HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nu Skin Refreshes Anti-Aging System With PHA Ingredients

This article was originally published in The Rose Sheet

Executive Summary

Nu Skin is relaunching Nu Skin 180° Anti-Aging Skin Therapy System with formulas containing polyhydroxy acids to offer a less aggressive regimen positioned for all skin types, the direct seller said

You may also be interested in...



“Aging Interruption,” Global Expansion Will Grow Nu Skin In 2007 – Chang

Nu Skin will strengthen brand equity in the New Year with new technology, expansion in Asia and a renewed commitment to direct selling, the company said during a Nov. 30 investors conference in New York City

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel